Adverse Events Following the BNT162b2 mRNA COVID-19 Vaccine (Pfizer-BioNTech) in Aotearoa New Zealand

INTRODUCTION: In February 2021, New Zealand began its largest ever immunisation programme with the BNT162b2 mRNA coronavirus disease 2019 (COVID-19) vaccine. OBJECTIVE: We aimed to understand the association between 12 adverse events of special interest (AESIs) and a primary dose of BNT162b2 in the...

Descripción completa

Detalles Bibliográficos
Autores principales: Walton, Muireann, Pletzer, Vadim, Teunissen, Thomas, Lumley, Thomas, Hanlon, Timothy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10442303/
https://www.ncbi.nlm.nih.gov/pubmed/37556109
http://dx.doi.org/10.1007/s40264-023-01332-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10442303/
https://www.ncbi.nlm.nih.gov/pubmed/37556109
http://dx.doi.org/10.1007/s40264-023-01332-1

Ejemplares similares